Compare PRAX & AXTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | AXTI |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 8.1B |
| IPO Year | 2020 | 1998 |
| Metric | PRAX | AXTI |
|---|---|---|
| Price | $322.54 | $57.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 3 |
| Target Price | ★ $572.13 | $50.50 |
| AVG Volume (30 Days) | 548.0K | ★ 8.4M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $99,361,000.00 |
| Revenue This Year | N/A | $44.70 |
| Revenue Next Year | $7,758.26 | $42.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.09 |
| 52 Week Low | $37.25 | $1.85 |
| 52 Week High | $366.52 | $143.16 |
| Indicator | PRAX | AXTI |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 36.81 |
| Support Level | $282.49 | $53.36 |
| Resistance Level | $344.07 | $71.49 |
| Average True Range (ATR) | 21.29 | 8.41 |
| MACD | 2.92 | -1.16 |
| Stochastic Oscillator | 54.65 | 8.32 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.